Biosimulation Market By Product (Software, Services), By Application (Drug Development, Drug Discovery, Others), By Delivery model (Subscription Model, Ownership Model), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizati

Biosimulation Market By Product (Software, Services), By Application (Drug Development, Drug Discovery, Others), By Delivery model (Subscription Model, Ownership Model), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization (CROs), Academic and Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032


The Biosimulation Market was valued for $2,452.31 million in 2022 and is estimated to reach $10,573.52 million by 2032, exhibiting a CAGR of 15.8% from 2023 to 2032. Biosimulation uses computer-based mathematical simulations to replicate biological processes, dynamics, and systems. Model-based predictions software such as biosimulation allow researchers to gather important data about how biological systems behave without having to conduct such tests in living organisms, including humans and animals.

Pre-clinical testing of novel medicines, lead identification and optimization, target identification and validation are some primary areas where biosimulation is being used in drug R&D. Biosimulation forms the backbone of “virtual” drug trials, whose aim is to accurately predict the way medicines and diseases behave in the body by applying principles from biology, chemistry, and pharmacology with proprietary algorithms. In addition, this work includes gathering critical insights concerning drug interactions, safe dosing, toxicity predictions, and more.

Major factors that drive the growth of the global biosimulation market include an increase in demand for drug discovery and development, rise in need for personalized medicines, and surge in technological advancement in biosimulation software and devices. For instance, in June 2022, Certara, a global leader in biosimulation, released the new versions of immunogenicity (IG), immuno-oncology (IO) and vaccine simulators to help predict how drugs work and address key questions in the development of novel biologic therapies.

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, diabetes, Alzheimer's, cardiovascular disease, kidney disorders, and various others are the major factors that increase the demand for biosimulation software and hence propel the growth of the market. In addition, rise in demand to reduce drug discovery and development costs and increase in penetration of biosimulation software in contract research organization (CROs) and academic research institutes for drug discovery and development are the major factors that boost the growth of the biosimulation market.

However, the lack of standardized formats, protocols, and interoperability between different simulation platforms and limited awareness and education about biosimulation techniques among researchers and healthcare professionals restrain the growth of the biosimulation market. On the contrary, the expanding applications and increased use of personalized medicine and biosimulation solutions for pediatric drug development are expected to provide additional opportunities for the biosimulation market to grow in the coming years.

The global biosimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into software and services. On the basis of delivery model, the market is segmented into subscription model and ownership model. On the basis of application, it is segregated into drug development, drug discovery and others. On the basis of end user, it is segmented into pharmaceutical and biotechnology companies, contract research organization (CROs) and academic and research institutes. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Dassault Systemes, VeriSIM Life, Certara Inc, Genedata AG, SimBioSys, Physiomics PLC, INOSIM Software GmbH, Schrodinger, Inc. Simulation Plus Inc, and Cadence Design Systems, Inc. The key players such as Simulation Plus Inc, Cadence Design Systems Inc, VeriSIM Life, Certara Inc, Schrodinger Inc, and Genedata AG have adopted product launch, acquisition, collaboration, partnership, and business expansion as major developmental strategies to improve the product portfolio of the biosimulation market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimulation market analysis from 2022 to 2032 to identify the prevailing biosimulation market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the biosimulation market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global biosimulation market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

Software
Services

By Application

Drug Development
Drug Discovery
Others

By Delivery model

Subscription Model
Ownership Model

By End User

Pharmaceutical and Biotechnology Companies
Contract Research Organization (CROs)
Academic and Research Institutes

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa
Key Market Players
SimBioSys
Physiomics Plc
Genedata AG
Simulations Plus, Inc.
Cadence Design Systems, Inc.
Certara, Inc.
VeriSIM Life
Schrodinger, Inc.
Dassault Systemes
INOSIM Software GmbH

Please Note: It will take 7-10 business days to complete the report upon order confirmation.


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growth in adoption of biosimulation software
3.4.1.2. Technological advancements in biosimulation software
3.4.1.3. Increase in demand to curtail drug discovery and development costs
3.4.2. Restraints
3.4.2.1. Lack of standardization and interoperability
3.4.3. Opportunities
3.4.3.1. Expansion of applications of biosimulation and increase in demand for personalized medicine.
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BIOSIMULATION MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Software
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Services
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: BIOSIMULATION MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Drug Development
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Drug Discovery
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: BIOSIMULATION MARKET, BY DELIVERY MODEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Subscription Model
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Ownership Model
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: BIOSIMULATION MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Pharmaceutical and Biotechnology Companies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Contract Research Organization (CROs)
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Academic and Research Institutes
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: BIOSIMULATION MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Product
8.2.3. Market size and forecast, by Application
8.2.4. Market size and forecast, by Delivery model
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Product
8.2.6.1.2. Market size and forecast, by Application
8.2.6.1.3. Market size and forecast, by Delivery model
8.2.6.1.4. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Product
8.2.6.2.2. Market size and forecast, by Application
8.2.6.2.3. Market size and forecast, by Delivery model
8.2.6.2.4. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Product
8.2.6.3.2. Market size and forecast, by Application
8.2.6.3.3. Market size and forecast, by Delivery model
8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Product
8.3.3. Market size and forecast, by Application
8.3.4. Market size and forecast, by Delivery model
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Product
8.3.6.1.2. Market size and forecast, by Application
8.3.6.1.3. Market size and forecast, by Delivery model
8.3.6.1.4. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Product
8.3.6.2.2. Market size and forecast, by Application
8.3.6.2.3. Market size and forecast, by Delivery model
8.3.6.2.4. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Product
8.3.6.3.2. Market size and forecast, by Application
8.3.6.3.3. Market size and forecast, by Delivery model
8.3.6.3.4. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Product
8.3.6.4.2. Market size and forecast, by Application
8.3.6.4.3. Market size and forecast, by Delivery model
8.3.6.4.4. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Product
8.3.6.5.2. Market size and forecast, by Application
8.3.6.5.3. Market size and forecast, by Delivery model
8.3.6.5.4. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Product
8.3.6.6.2. Market size and forecast, by Application
8.3.6.6.3. Market size and forecast, by Delivery model
8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Product
8.4.3. Market size and forecast, by Application
8.4.4. Market size and forecast, by Delivery model
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Product
8.4.6.1.2. Market size and forecast, by Application
8.4.6.1.3. Market size and forecast, by Delivery model
8.4.6.1.4. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Product
8.4.6.2.2. Market size and forecast, by Application
8.4.6.2.3. Market size and forecast, by Delivery model
8.4.6.2.4. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Market size and forecast, by Product
8.4.6.3.2. Market size and forecast, by Application
8.4.6.3.3. Market size and forecast, by Delivery model
8.4.6.3.4. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Market size and forecast, by Product
8.4.6.4.2. Market size and forecast, by Application
8.4.6.4.3. Market size and forecast, by Delivery model
8.4.6.4.4. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Product
8.4.6.5.2. Market size and forecast, by Application
8.4.6.5.3. Market size and forecast, by Delivery model
8.4.6.5.4. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Product
8.4.6.6.2. Market size and forecast, by Application
8.4.6.6.3. Market size and forecast, by Delivery model
8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Product
8.5.3. Market size and forecast, by Application
8.5.4. Market size and forecast, by Delivery model
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Latin America
8.5.6.1.1. Market size and forecast, by Product
8.5.6.1.2. Market size and forecast, by Application
8.5.6.1.3. Market size and forecast, by Delivery model
8.5.6.1.4. Market size and forecast, by End User
8.5.6.2. Middle East
8.5.6.2.1. Market size and forecast, by Product
8.5.6.2.2. Market size and forecast, by Application
8.5.6.2.3. Market size and forecast, by Delivery model
8.5.6.2.4. Market size and forecast, by End User
8.5.6.3. Africa
8.5.6.3.1. Market size and forecast, by Product
8.5.6.3.2. Market size and forecast, by Application
8.5.6.3.3. Market size and forecast, by Delivery model
8.5.6.3.4. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Certara, Inc.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.0. Key strategic moves and developments
10.2. Dassault Systemes
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Simulations Plus, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.0. Key strategic moves and developments
10.4. Genedata AG
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.0. Key strategic moves and developments
10.5. SimBioSys
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.6. Physiomics Plc
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. INOSIM Software GmbH
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. VeriSIM Life
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.0. Key strategic moves and developments
10.9. Schrodinger, Inc.
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.0. Key strategic moves and developments
10.10. Cadence Design Systems, Inc.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.0. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. BIOSIMULATION MARKET FOR SOFTWARE, BY REGION, 2022-2032 ($MILLION)
TABLE 03. BIOSIMULATION MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 05. BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY REGION, 2022-2032 ($MILLION)
TABLE 06. BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION, 2022-2032 ($MILLION)
TABLE 07. BIOSIMULATION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 09. BIOSIMULATION MARKET FOR SUBSCRIPTION MODEL, BY REGION, 2022-2032 ($MILLION)
TABLE 10. BIOSIMULATION MARKET FOR OWNERSHIP MODEL, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 12. BIOSIMULATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATION (CROS), BY REGION, 2022-2032 ($MILLION)
TABLE 14. BIOSIMULATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. BIOSIMULATION MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 21. U.S. BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 22. U.S. BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 23. U.S. BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 24. U.S. BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 25. CANADA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 26. CANADA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. CANADA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 28. CANADA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. MEXICO BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 30. MEXICO BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. MEXICO BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 32. MEXICO BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. EUROPE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 34. EUROPE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. EUROPE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 36. EUROPE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 37. EUROPE BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 38. GERMANY BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 39. GERMANY BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 40. GERMANY BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 41. GERMANY BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. FRANCE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 43. FRANCE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. FRANCE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 45. FRANCE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 46. UK BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 47. UK BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. UK BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 49. UK BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 50. ITALY BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 51. ITALY BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. ITALY BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 53. ITALY BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. SPAIN BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 55. SPAIN BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 56. SPAIN BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 57. SPAIN BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. REST OF EUROPE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 59. REST OF EUROPE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. REST OF EUROPE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. ASIA-PACIFIC BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 63. ASIA-PACIFIC BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. ASIA-PACIFIC BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 67. JAPAN BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 68. JAPAN BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 69. JAPAN BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 70. JAPAN BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 71. CHINA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 72. CHINA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 73. CHINA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 74. CHINA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 75. AUSTRALIA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 76. AUSTRALIA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 77. AUSTRALIA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 78. AUSTRALIA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 79. INDIA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 80. INDIA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. INDIA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 82. INDIA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. SOUTH KOREA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 84. SOUTH KOREA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 91. LAMEA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 92. LAMEA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 93. LAMEA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 94. LAMEA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 95. LAMEA BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 96. LATIN AMERICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 97. LATIN AMERICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 98. LATIN AMERICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 99. LATIN AMERICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 100. MIDDLE EAST BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 101. MIDDLE EAST BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 102. MIDDLE EAST BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 103. MIDDLE EAST BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 104. AFRICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 105. AFRICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 106. AFRICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 107. AFRICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 108. CERTARA, INC.: KEY EXECUTIVES
TABLE 109. CERTARA, INC.: COMPANY SNAPSHOT
TABLE 110. CERTARA, INC.: SERVICE SEGMENTS
TABLE 111. CERTARA, INC.: PRODUCT PORTFOLIO
TABLE 112. CERTARA, INC.: KEY STRATERGIES
TABLE 113. DASSAULT SYSTEMES: KEY EXECUTIVES
TABLE 114. DASSAULT SYSTEMES: COMPANY SNAPSHOT
TABLE 115. DASSAULT SYSTEMES: PRODUCT SEGMENTS
TABLE 116. DASSAULT SYSTEMES: PRODUCT PORTFOLIO
TABLE 117. SIMULATIONS PLUS, INC.: KEY EXECUTIVES
TABLE 118. SIMULATIONS PLUS, INC.: COMPANY SNAPSHOT
TABLE 119. SIMULATIONS PLUS, INC.: SERVICE SEGMENTS
TABLE 120. SIMULATIONS PLUS, INC.: PRODUCT PORTFOLIO
TABLE 121. SIMULATIONS PLUS, INC.: KEY STRATERGIES
TABLE 122. GENEDATA AG: KEY EXECUTIVES
TABLE 123. GENEDATA AG: COMPANY SNAPSHOT
TABLE 124. GENEDATA AG: PRODUCT SEGMENTS
TABLE 125. GENEDATA AG: PRODUCT PORTFOLIO
TABLE 126. GENEDATA AG: KEY STRATERGIES
TABLE 127. SIMBIOSYS: KEY EXECUTIVES
TABLE 128. SIMBIOSYS: COMPANY SNAPSHOT
TABLE 129. SIMBIOSYS: SERVICE SEGMENTS
TABLE 130. SIMBIOSYS: PRODUCT PORTFOLIO
TABLE 131. PHYSIOMICS PLC: KEY EXECUTIVES
TABLE 132. PHYSIOMICS PLC: COMPANY SNAPSHOT
TABLE 133. PHYSIOMICS PLC: SERVICE SEGMENTS
TABLE 134. PHYSIOMICS PLC: PRODUCT PORTFOLIO
TABLE 135. INOSIM SOFTWARE GMBH: KEY EXECUTIVES
TABLE 136. INOSIM SOFTWARE GMBH: COMPANY SNAPSHOT
TABLE 137. INOSIM SOFTWARE GMBH: SERVICE SEGMENTS
TABLE 138. INOSIM SOFTWARE GMBH: PRODUCT PORTFOLIO
TABLE 139. VERISIM LIFE: KEY EXECUTIVES
TABLE 140. VERISIM LIFE: COMPANY SNAPSHOT
TABLE 141. VERISIM LIFE: SERVICE SEGMENTS
TABLE 142. VERISIM LIFE: PRODUCT PORTFOLIO
TABLE 143. VERISIM LIFE: KEY STRATERGIES
TABLE 144. SCHRODINGER, INC.: KEY EXECUTIVES
TABLE 145. SCHRODINGER, INC.: COMPANY SNAPSHOT
TABLE 146. SCHRODINGER, INC.: SERVICE SEGMENTS
TABLE 147. SCHRODINGER, INC.: PRODUCT PORTFOLIO
TABLE 148. SCHRODINGER, INC.: KEY STRATERGIES
TABLE 149. CADENCE DESIGN SYSTEMS, INC.: KEY EXECUTIVES
TABLE 150. CADENCE DESIGN SYSTEMS, INC.: COMPANY SNAPSHOT
TABLE 151. CADENCE DESIGN SYSTEMS, INC.: SERVICE SEGMENTS
TABLE 152. CADENCE DESIGN SYSTEMS, INC.: PRODUCT PORTFOLIO
TABLE 153. CADENCE DESIGN SYSTEMS, INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. BIOSIMULATION MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF BIOSIMULATION MARKET,2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN BIOSIMULATION MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW INTENSITY OF RIVALRY
FIGURE 08. LOW BARGAINING POWER OF BUYERS
FIGURE 09. GLOBAL BIOSIMULATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. BIOSIMULATION MARKET, BY PRODUCT, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SOFTWARE, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SERVICES, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. BIOSIMULATION MARKET, BY APPLICATION, 2022(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SUBSCRIPTION MODEL, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR OWNERSHIP MODEL, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. BIOSIMULATION MARKET, BY END USER, 2022(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATION (CROS), BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. BIOSIMULATION MARKET BY REGION, 2022(%)
FIGURE 25. U.S. BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 26. CANADA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 27. MEXICO BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 28. GERMANY BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 29. FRANCE BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 30. UK BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 31. ITALY BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 32. SPAIN BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 33. REST OF EUROPE BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 34. JAPAN BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 35. CHINA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 36. AUSTRALIA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 37. INDIA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 38. SOUTH KOREA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 39. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 40. LATIN AMERICA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 41. MIDDLE EAST BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 42. AFRICA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47. COMPETITIVE DASHBOARD
FIGURE 48. COMPETITIVE HEATMAP: BIOSIMULATION MARKET
FIGURE 49. TOP PLAYER POSITIONING, 2022
FIGURE 50. CERTARA, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 51. CERTARA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. CERTARA, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. DASSAULT SYSTEMES: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 54. DASSAULT SYSTEMES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. DASSAULT SYSTEMES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. SIMULATIONS PLUS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. SIMULATIONS PLUS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. SIMULATIONS PLUS, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. PHYSIOMICS PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 60. SCHRODINGER, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 61. SCHRODINGER, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. SCHRODINGER, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 63. CADENCE DESIGN SYSTEMS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 64. CADENCE DESIGN SYSTEMS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. CADENCE DESIGN SYSTEMS, INC.: REVENUE SHARE BY REGION, 2022 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings